万泰生物(603392.SH)：重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请获得受理

智通财经2025-12-25

智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限公司收到国家药品监督管理局行政许可文书《受理通知书》，公司申报的“重组三价轮状病毒亚单位疫苗(大肠埃希菌)”临床试验申请已获得受理。此次重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请的受理，是公司创新疫苗研发过程中的重要一步，标志着公司基于大肠埃希菌自主技术平台的重组蛋白疫苗研发战略又取得...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2594387092?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-25 16:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594387092","market":"fut","top_or_hot":-1,"title":"万泰生物(603392.SH)：重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请获得受理","media":"智通财经","content":"<div>\n<p>智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限公司收到国家药品监督管理局行政许可文书《受理通知书》，公司申报的“重组三价轮状病毒亚单位疫苗(大肠埃希菌)”临床试验申请已获得受理。此次重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请的受理，是公司创新疫苗研发过程中的重要一步，标志着公司基于大肠埃希菌自主技术平台的重组蛋白疫苗研发战略又取得...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1385816.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>万泰生物(603392.SH)：重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请获得受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n万泰生物(603392.SH)：重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请获得受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-25 16:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1385816.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限公司收到国家药品监督管理局行政许可文书《受理通知书》，公司申报的“重组三价轮状病毒亚单位疫苗(大肠埃希菌)”临床试验申请已获得受理。此次重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请的受理，是公司创新疫苗研发过程中的重要一步，标志着公司基于大肠埃希菌自主技术平台的重组蛋白疫苗研发战略又取得...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1385816.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1200","symbol_name":"软饮料","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1385816.html","article_id":"2594387092","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594387092","pubTimestamp":1766649935,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限公司收到国家药品监督管理局行政许可文书《受理通知书》，公司申报的“重组三价轮状病毒亚单位疫苗(大肠埃希菌)”临床试验申请已获得受理。此次重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请的受理，是公司创新疫苗研发过程中的重要一步，标志着公司基于大肠埃希菌自主技术平台的重组蛋白疫苗研发战略又取得关键进展，若该产品研发未来成功上市，将有利于丰富公司产品布局，进一步提高公司市场竞争力。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","603392":"万泰生物","BK1200":"软饮料","BK0239":"医药制造","BK1589":"北水核心资产","LU1981816686.USD":"EASTSPRING INV ASIAN MULTI FACTOR EQUITY \"A\" (USD) ACC","09633":"农夫山泉"},"translate_title":"Wantai Bio (603392. SH): Recombinant trivalent rotavirus subunit vaccine (Escherichia coli) clinical trial application accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1.5,"603392":1.5,"09633":1.5},"content_text":"智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限公司收到国家药品监督管理局行政许可文书《受理通知书》，公司申报的“重组三价轮状病毒亚单位疫苗(大肠埃希菌)”临床试验申请已获得受理。此次重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请的受理，是公司创新疫苗研发过程中的重要一步，标志着公司基于大肠埃希菌自主技术平台的重组蛋白疫苗研发战略又取得关键进展，若该产品研发未来成功上市，将有利于丰富公司产品布局，进一步提高公司市场竞争力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594387092","isCrawlerRequest":true}